Role of Erlotinib in Influencing the Quality of Life of Cancer Patients

Clinical Cancer Drugs ◽

10.2174/2212697x07999200820162006 ◽

2020 ◽

Vol 07 ◽

Author(s):

Deepika Purohit ◽

Parijat Pandey

Keyword(s):

Quality Of Life ◽

Lung Cancer ◽

Cancer Patients ◽

Kinase Inhibitors ◽

Treatment Modalities ◽

Pancreatic Cancers ◽

Review Reports ◽

Causes Of Deaths

Background:: Cancer is one of the significant causes of morbidity and mortality in patients globally. Lung cancer, among other cancers, remains to be one of the principal causes of deaths in both men and women. The most common type of lung cancer is the non-small-cell lung cancer (NSCLC). Apart from lung cancer, pancreatic cancer is also one of the common cancers currently. Objective:: The assessment of QoL in erlotinib-treated patients can also prove to be very useful in the establishment of this drug as the main treatment option for the patients with pancreatic and lung cancer. Methods:: Therapies that target EGFR-mediated signalling are the latest keystones for treating these two types of cancers. They comprise of two main treatment modalities: firstly, against the extracellular fields, that include monoclonal antibodies and secondly, mechanisms that create interferences in the signalling pathways, primarily the small molecule tyrosine kinase inhibitors. Results:: Quality of life (QoL) is one of the key advantages in erlotinib therapy over chemotherapy. Conclusion:: The present review reports the role of erlotinib in improving the quality of life of cancer patients especially in NSCLC and pancreatic cancers. The studies or trials establishing the relations between erlotinib and QoL are discussed in detail in this review.

Download Full-text

Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors

Journal of Oncology Pharmacy Practice ◽

10.1177/1078155220946381 ◽

2020 ◽

pp. 107815522094638

Author(s):

Jelena Rosentreter ◽

Jürgen Alt ◽

Marius Fried ◽

Geothy Chakupurakal ◽

Jan Stratmann ◽

...

Keyword(s):

Quality Of Life ◽

Lung Cancer ◽

Medication Adherence ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Cancer Patients ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

Kinase Inhibitor

Introduction Cancer patients tend to prefer oral instead of parenteral chemotherapy. To date, there is little evidence on the medication adherence in cancer patients. We investigated medication adherence to tyrosine kinase inhibitors in patients suffering from non-small cell lung cancer. Methods Tyrosine kinase inhibitor adherence was measured electronically by MEMS® (medication event monitoring system) over at least six months. Adherence rates were calculated in terms of Dosing Compliance, Timing Compliance, Taking Compliance, and Drug Holidays. Patients were dichotomized as adherent when Dosing Compliance and Timing Compliance were ≥80%, Taking Compliance ranged between 90 and 110%, and <1 Drug Holiday was registered. Quality of life was assessed by two questionnaires (EORTC QLQ-C30 version 3.0, EORTC QLQ-LC13) at three time points. Adverse drug events were reported via patient diaries. Results Out of 32 patients enrolled, data from 23 patients were evaluable. Median Dosing Compliance, Taking Compliance, and Timing Compliance adherence rates of tyrosine kinase inhibitor intake amounted to 100%, 98%, and 99%, respectively; Drug Holidays were observed in three patients. Four patients were dichotomized as non-adherent. Three of them had a twice-daily tyrosine kinase inhibitor regimen. Median quality of life scores amounted to 67 (max. 100) and remained unchanged over the study period. Fatigue and rash were the most frequently reported adverse drug events. Conclusion Medication adherence of non-small cell lung cancer patients treated with tyrosine kinase inhibitors was extraordinarily high and is likely to support the effectiveness of tyrosine kinase inhibitor treatment and a good quality of life over a long period of time. Adherence facilitating information and education is especially relevant for patients taking tyrosine kinase inhibitors in a twice-daily regimen.

Download Full-text

Posttraumatic Growth, Quality of Life, and Survival Among Lung Cancer Patients

PsycEXTRA Dataset ◽

10.1037/e711332011-001 ◽

2011 ◽

Author(s):

Angela L. Dougall ◽

Jeffrey N. Swanson ◽

Andrew Baum

Keyword(s):

Quality Of Life ◽

Lung Cancer ◽

Posttraumatic Growth ◽

Cancer Patients ◽

Lung Cancer Patients ◽

Growth Quality

Download Full-text

P3.15-04 An Interdisciplinary Educational Program Dedicated to Non-Small Cell Lung Cancer Patients to Improve their Quality of Life

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2018.08.1880 ◽

2018 ◽

Vol 13 (10) ◽

pp. S992

Author(s):

L. Bigay-Gamé

Keyword(s):

Quality Of Life ◽

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Cell Lung Cancer ◽

Educational Program ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancer Patients

Download Full-text

Integrative Treatment of Lung Cancer Patients: Observational Study of 57 Cases

Asian Journal of Oncology ◽

10.1055/s-0040-1722380 ◽

2021 ◽

Author(s):

Lorenzo Anelli ◽

Alessia Di Nardo ◽

Massimo Bonucci

Keyword(s):

Quality Of Life ◽

Lung Cancer ◽

Nutritional Status ◽

Cancer Patients ◽

Immune Status ◽

Conventional Medicine ◽

Integrative Therapy ◽

Lung Cancer Patients ◽

Retrospective Clinical Study

Abstract Introduction A retrospective clinical study was performed to identify the characteristics of patients with lung cancer treated with integrative cancer treatment in addition to conventional medicine. Materials and Methods We reviewed medical records for lung cancer patients who visited a single integrative setting in Rome, Italy. A total of 57 patients were included, and the majority had advanced-stage cancer. All of them underwent integrative therapy with nutrition and phytotherapy indications. The diet was designed to reduce most of possible factors promoting cancer proliferation, inflammation, and obesity. Foods with anti-inflammatory, prebiotic, antioxidant, and anticancer properties had been chosen. Herbal supplements with known effects on lung cancer were prescribed. In particular, astragal, apigenine, fucosterol, polydatin, epigallocatechin gallate, cannabis, curcumin, and inositol were used. Furthermore, medical mushrooms and other substances were used to improve the immune system and to reduce chemotherapy side effects. Five key parameters have been evaluated for 2 years starting at the first surgery: nutritional status, immune status, discontinuation of therapy, quality of life, and prognosis of the disease. Results A relevant improvement in parameters relative to nutritional status, immune status, and quality of life has been observed after integrative therapy compared with the same parameters at the first medical visit before starting such approach. Conclusion The results suggest that integrative therapy may have benefits in patients with lung cancer. Even though there are limitations, the study suggests that integrative therapy could improve nutritional status and quality of life, with possible positive effect on overall survival.

Download Full-text